Teen battling kidney disease hopes to help other youths with chronic conditionsNew Castle NewsGrace has agreed to try a new drug called Rituximab, which will be given to her intravenously in a one-time, six-hour treatment. She hopes that will help put …
Naturally acquired HPV16 antibodies reduced risk for infection, cervical …HealioNew data suggest that naturally acquired HPV16 antibodies are associated with a lower risk for infection and cervical abnormalities associated with the virus. To a lesser…
Daily News & Analysis |
NIH grantees sharpen understanding of antibodies that may cut risk of HIV …
Eureka! Science News What immune response should a vaccine elicit to prevent HIV infection? Two studies published online today bring scientists closer to answering this question by identifying previously unrecognized attributes of antibodies that appear to have reduced the … Lupus may end up saving livesVOXXI Past HIV vaccine trials pave way for new treatmentFree Press Journal |
|
North Shore-LIJ Cancer Institute Doctors’ Editorial Published in The New …
PR Web (press release) Researchers compared the benefits of obinutuzumab with that of another antibody rituximab, which also attacks CD20. Both drugs were combined with the chemotherapy drug chlorambucil. They found that subjects receiving obinutuzumab-chlorambucil had … |
|
Biogen Idec Inc (BIIB) news: Biogen’s Winning Strategy
Seeking Alpha In the same segment Biogen and partner AbbVie (ABBV) are developing daclizumab high-yield process (HYP) in relapsing-remitting multiple sclerosis. The companies have completed a Phase 2b trial and expect the results of the Phase 3 study in mid-2014. |
ANINEWS |
Past HIV vaccine trials pave way for new treatment
ANINEWS Washington, March 20 (ANI): A multi-national research team led by Duke Medicine scientists has identified a subclass of antibodies associated with an effective immune response to an HIV vaccine. Earlier analyses of the results of that trial, known as … Past HIV vaccine trials reveal new path to successR & D Magazine |
|
Xencor’s CEO Discusses Q4 2013 Results – Earnings Call Transcript
Seeking Alpha So that’s a potential significant differentiator for safety purposes from cytotoxic B-cell antibodies that are currently used in autoimmune disease such as rituximab. Now, our partner Amgen has an option to acquire the exclusive worldwide license to … |
Medscape |
Obinutuzumab Beats Rituximab in CLL
Medscape The new anti-CD20 antibody obinutuzumab (Gazya) performed better than the older product rituximab (Rituxan) when both were added to chemotherapy in previously untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities. North Shore-LIJ Cancer Institute doctors’ editorial publishedEurekAlert (press release) |
|
North Shore-LIJ Cancer Institute doctors’ editorial published
EurekAlert (press release) Researchers compared the benefits of obinutuzumab with that of another antibody rituximab, which also attacks CD20. Both drugs were combined with the chemotherapy drug chlorambucil. They found that subjects receiving obinutuzumab-chlorambucil had … |
Daily News & Analysis |
NIH grantees sharpen understanding of antibodies that may cut risk of HIV …
Science Codex What immune response should a vaccine elicit to prevent HIV infection? Two studies published online today bring scientists closer to answering this question by identifying previously unrecognized attributes of antibodies that appear to have reduced the … Past HIV Vaccine Trials Reveal New Path to SuccessNewswise (press release) Past HIV vaccine trials pave way for new treatmentANINEWS |